Welcome to Pink Sheet
Create an account to read this article
Already a subscriber?
FISCHER PHARMACEUTICALS LTD.’s TI-SCREEN NATURAL SUNSCREEN IS U.S. DEBUT
FISCHER PHARMACEUTICALS LTD.'s TI-SCREEN NATURAL SUNSCREEN IS U.S. DEBUT product by the Israeli dermatological product manufacturer's newly-acquired U.S. subsidiary, Fischer Pharmaceuticals, Inc. The parent firm recently purchased a 49% interest in Fischer (formerly T/I Pharmaceuticals) as an entry into the U.S. market. Fischer plans to begin promotions for the SPF 16 TI-Screen Natural sunscreen (active ingredient titanium dioxide) at the annual meeting of the American Academy of Dermatology in December. Fischer Pharmaceuticals, Ltd. has provided $250,000 to its subsidiary for working capital purposes and has assumed $1.4 mil. of T/I's $1.5 mil. in loans. Fischer plans to expand the firm's distribution; currently, two-thirds of the firm's business is in California. Fischer also plans to enlarge T/I's staff from its current 10 employees and relocate the company from Irvine to Sunnyvale, Calif. Hans Kaspar, who retired from SBH, formerly Sola Barnes-Hind, last June, is president and CEO of the U.S. operation. Kaspar, 62, was most recently VP-ophthalmic research at SBH and had worked for Barnes-Hind for 30 years, where he had been VP-R&D and international operations. In addition to TI-Screen sunscreens, U.S. Fischer products include TI-Cream moisturizer with hyaluronic acid for application on the face and neck and Ulactin body moisturizer with lactic acid and urea. Fischer Pharmaceuticals, Ltd. has manufacturing facilities in Tel Aviv and Germany. Three-quarters of the firm's $20 mil. in worldwide sales are generated in Israel. Company brands include Dr. Fischer baby care and lice treatment products and Ultrasol sunscreens.
More from Archive
• By
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
• By
This is your final call to participate in the survey to better understand our subscribers’ content and delivery needs. The deadline is 20 September.
• By
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
• By
A new pilot aims to take Brazil closer to ‘digital transformation.’
More from Pink Sheet
• By
Pink Sheet reporter and editors discuss the potential impact George Tidmarsh could have as director of the US FDA Center for Drug Evaluation and Research and the issues threatening the future of Sarepta’s gene therapy Elevidys.
• By
The European Medicines Agency’s human medicines committee, the CHMP, has recommended 14 new medicines for pan-EU approval this month, including five orphan medicines.
• By
The European Medicines Agency says that Eli Lilly's Alzheimer's disease drug should be approved for use in the EU, now that it has re-examined the negative opinion it previously adopted.